EP1687427A4 - METHODS OF MODULATING NEURONAL RESPONSES - Google Patents

METHODS OF MODULATING NEURONAL RESPONSES

Info

Publication number: EP1687427A4
Authority: EP; European Patent Office
Prior art keywords: methods; modulating neuronal; neuronal responses; responses; modulating
Prior art date: 2003-10-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP04789721A

Other languages

German (de)

French (fr)

Other versions

EP1687427A2 (en

EP1687427B1 (en

Inventor

Yu Tian Wang

Yushan Wang

Anthony Phillips

Lidong Liu

Yitao Liu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Qingdao Primedicine Pharmaceutical Co Ltd

Original Assignee

University of British Columbia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-08

Filing date

2004-10-08

Publication date

2007-07-18

2004-10-08 Application filed by University of British Columbia filed Critical University of British Columbia

2006-08-09 Publication of EP1687427A2 publication Critical patent/EP1687427A2/en

2007-07-18 Publication of EP1687427A4 publication Critical patent/EP1687427A4/en

2016-08-24 Application granted granted Critical

2016-08-24 Publication of EP1687427B1 publication Critical patent/EP1687427B1/en

2024-10-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biotechnology (AREA)

EP04789721.0A 2003-10-08 2004-10-08 Methods for modulating neuronal responses Expired - Lifetime EP1687427B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50924903P	2003-10-08	2003-10-08
PCT/CA2004/001813 WO2005033311A2 (en)	2003-10-08	2004-10-08	Methods for modulating neuronal responses using inhibitors of ampa receptor endocytosis

Publications (3)

Publication Number	Publication Date
EP1687427A2 EP1687427A2 (en)	2006-08-09
EP1687427A4 true EP1687427A4 (en)	2007-07-18
EP1687427B1 EP1687427B1 (en)	2016-08-24

Family

ID=34421804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04789721.0A Expired - Lifetime EP1687427B1 (en)	2003-10-08	2004-10-08	Methods for modulating neuronal responses

Country Status (6)

Country	Link
US (2)	US20060234912A1 (en)
EP (1)	EP1687427B1 (en)
JP (1)	JP2008500266A (en)
CA (2)	CA2445743A1 (en)
ES (1)	ES2605015T3 (en)
WO (1)	WO2005033311A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) *	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) *	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
US9597395B2 (en)	2001-12-07	2017-03-21	Cytori Therapeutics, Inc.	Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en)	2001-12-07	2005-05-05	Fraser John K.	Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7771716B2 (en)	2001-12-07	2010-08-10	Cytori Therapeutics, Inc.	Methods of using regenerative cells in the treatment of musculoskeletal disorders
US8105580B2 (en)	2001-12-07	2012-01-31	Cytori Therapeutics, Inc.	Methods of using adipose derived stem cells to promote wound healing
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
UA87453C2 (en) *	2003-02-01	2009-07-27	Вайет	Use a fragment ав for treatment of alzheimer's disease
GB0416730D0 (en)	2004-07-27	2004-09-01	Novartis Ag	Organic compounds
WO2006066089A1 (en)	2004-12-15	2006-06-22	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
GB0507298D0 (en)	2005-04-11	2005-05-18	Novartis Ag	Organic compounds
WO2010044803A1 (en) *	2008-10-17	2010-04-22	Elan Pharma International Limited	Treatment of amyloidogenic diseases
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
EP2059598B1 (en) *	2006-08-31	2014-03-19	Centre for Addiction and Mental Health	Compositions and methods for modulating ampa receptor-mediated excitotoxicity
US8536115B2 (en)	2006-08-31	2013-09-17	Centre For Addiction And Mental Health	Compositions and methods for modulating AMPA receptor-mediated excitotoxicity
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
ES2498040T3 (en) *	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases with humanized anti-beta antibodies
JO3076B1 (en)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	Immunotherapy regimes dependent on apoe status
US9745567B2 (en)	2008-04-28	2017-08-29	Revalesio Corporation	Compositions and methods for treating multiple sclerosis
US8586706B2 (en)	2007-10-25	2013-11-19	Kagoshima University	Peptide vaccine using mimic molecules of amyloid β peptide
US9523090B2 (en)	2007-10-25	2016-12-20	Revalesio Corporation	Compositions and methods for treating inflammation
US10125359B2 (en)	2007-10-25	2018-11-13	Revalesio Corporation	Compositions and methods for treating inflammation
WO2010021993A1 (en)	2008-08-19	2010-02-25	Cytori Therapeutics, Inc.	Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
EA201892184A1 (en)	2010-03-01	2019-03-29	БАЙЕР ХЕЛЬСКЕР ЛЛСи	OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR
US9994443B2 (en)	2010-11-05	2018-06-12	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
WO2013070011A1 (en) *	2011-11-09	2013-05-16	서울대학교산학협력단	Pharmaceutical composition for the prevention or treatment of neurological diseases comprising an ampa receptor endocytosis inhibitor
AU2014293138A1 (en) *	2013-07-23	2016-02-25	Revalesio Corporation	Compositions and methods for upregulating hippocampal plasticity and hippocampus-dependent learning and memory
WO2015120388A1 (en) *	2014-02-10	2015-08-13	Cytori Therapeutics, Inc.	Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CN106632601B (en) *	2016-11-16	2020-10-20	中国科学院昆明动物研究所	Short peptide for blocking synapse long-term potentiation (LTP) and application thereof
WO2019145957A1 (en) *	2018-01-28	2019-08-01	Technion Research & Development Foundation Limited	Method of treating intellectual disability, autism and epilepsy associated with an iqsec2 mutation and for identifying medicaments for treating the same
WO2020103889A1 (en) *	2018-11-21	2020-05-28	青岛普美圣医药科技有限公司	Method and medicine for treating depressive disorders
RO135590A1 (en) *	2020-08-31	2022-03-30	Szedlacsek Ştefan Eugen	Interference peptides as inhibitors of ampa receptor endocytosis interactions
CN114870192B (en) *	2022-03-26	2024-05-14	天津工业大学	Analysis method for synaptic plasticity LTP regulation and control by music rhythm magnetic field generated by soothing tracks
CN115925813B (en) *	2022-07-19	2024-05-17	青岛大学	Transmembrane cyclic peptide and its preparation method and use
WO2024199436A1 (en) *	2023-03-31	2024-10-03	青岛普美圣医药科技有限公司	Polypeptide active molecule having extended half-life and improved stability

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6383764B1 (en) *	2000-04-28	2002-05-07	The Regents Of The University Of California	Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5731410A (en) *	1994-11-28	1998-03-24	University Of Utah Research Foundation	Peptide for blocking autoantibody-evoked activation of glutamate receptor type 3 (GLUR3)
AU2001266787A1 (en) *	2000-06-07	2002-01-08	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
JP2014504503A (en) *	2010-12-28	2014-02-24	ゾーマテクノロジーリミテッド	Cell surface display using PDZ domains

2003
- 2003-10-20 CA CA002445743A patent/CA2445743A1/en not_active Abandoned
2004
- 2004-10-08 JP JP2006529523A patent/JP2008500266A/en not_active Withdrawn
- 2004-10-08 EP EP04789721.0A patent/EP1687427B1/en not_active Expired - Lifetime
- 2004-10-08 ES ES04789721.0T patent/ES2605015T3/en not_active Expired - Lifetime
- 2004-10-08 CA CA002542002A patent/CA2542002A1/en not_active Abandoned
- 2004-10-08 WO PCT/CA2004/001813 patent/WO2005033311A2/en not_active Ceased
2006
- 2006-04-06 US US11/399,840 patent/US20060234912A1/en not_active Abandoned
2011
- 2011-04-22 US US13/066,700 patent/US9486472B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6383764B1 (en) *	2000-04-28	2002-05-07	The Regents Of The University Of California	Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMADIAN GHOLAMREZA ET AL: "Tyrosine phosphorylation of GluR2 is required for insulin-stimulated AMPA receptor endocytosis and LTD", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 23, no. 5, 10 March 2004 (2004-03-10), pages 1040 - 1050, XP002430623, ISSN: 0261-4189 *
DATABASE REGISTRY [online] XP002430624, retrieved from STN Database accession no. 405140-74-1 *
See also references of WO2005033311A2 *

Also Published As

Publication number	Publication date
CA2542002A1 (en)	2005-04-14
ES2605015T3 (en)	2017-03-10
WO2005033311A2 (en)	2005-04-14
WO2005033311A3 (en)	2005-10-27
EP1687427A2 (en)	2006-08-09
CA2445743A1 (en)	2005-04-08
US9486472B2 (en)	2016-11-08
JP2008500266A (en)	2008-01-10
EP1687427B1 (en)	2016-08-24
US20060234912A1 (en)	2006-10-19
US20120077751A1 (en)	2012-03-29

Publication	Publication Date	Title
EP1687427A4 (en)	2007-07-18	METHODS OF MODULATING NEURONAL RESPONSES
DE60312873D1 (en)	2007-05-10	ELECTRO-SURGICAL INSTRUMENT FOR CLOSING VESSELS
EP1662993A4 (en)	2010-05-26	METHODS AND APPARATUS FOR BIOIMPEDANCE
ATE456558T1 (en)	2010-02-15	GABANERGIC MODULATORS
DE60309110D1 (en)	2006-11-30	Nerve stimulation device
DE602005009748D1 (en)	2008-10-23	3-PHENYL-PYRAZOL DERIVATIVES AS MODULATORS OF THE BENEFICIAL SOURCES OF TREATING 5-HT-2A-SEROTONINE RECEPTOR
DK1620551T3 (en)	2014-01-13	Phospholipase and process for its preparation
EP1633311A4 (en)	2009-06-03	COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTATHION REDUCTASE
EP1597349A4 (en)	2007-02-14	METHODS OF SCREENING TRPM5 MODULATORS
EP1491212A4 (en)	2009-10-28	MEANS FOR THE TREATMENT OF SLEEP DISORDERS
ITMI20031061A1 (en)	2003-11-28	PROCEDURE AND DEVICE FOR MODULATION
FR2838179B1 (en)	2004-12-24	BACKLIGHT APPARATUS
BRPI0515518A (en)	2008-07-29	loxapine analogues and methods of their use
EP1922661A4 (en)	2009-11-04	METHODS OF CHARACTERIZING MODULATORS OF BIOLOGICAL MOLECULES
EP1767243A4 (en)	2009-06-17	IONTOPHORESIS APPARATUS
EP1680104A4 (en)	2008-09-03	COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS WITH APIGENINE AS A CHINDROREGENERATIVE MEDIUM
DK1581307T3 (en)	2015-01-05	IRS MODULATORS
FR2836748B1 (en)	2004-08-27	SPRING-TYPE SOUNDPROOFER
MA26233A1 (en)	2004-07-01	CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
EP2018553A4 (en)	2011-09-07	ASSESSMENT OF TREATMENT OF MEAT
EP1870131A4 (en)	2009-10-21	DEVICE FOR PREVENTING CHAMBER FLAVORS AND DEVICE FOR REMOVING CHAMBER FLAVORS
EP1700056A4 (en)	2010-07-07	DEVICE AND METHOD FOR REALIZING MULTIPLE ANASTOMOSES
EP1526400A4 (en)	2006-07-05	ELECTRO-OPTICAL MODULATION ELEMENT
NO20033191D0 (en)	2003-07-11	color modulator
DE602004026067D1 (en)	2010-04-29	Device for the treatment of feet

Legal Events

Date	Code	Title	Description
2006-07-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-08-09	17P	Request for examination filed	Effective date: 20060508
2006-08-09	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2007-01-17	DAX	Request for extension of the european patent (deleted)
2007-07-18	A4	Supplementary search report drawn up and despatched	Effective date: 20070620
2009-07-22	17Q	First examination report despatched	Effective date: 20090623
2016-02-29	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2016-03-13	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2016-03-30	INTG	Intention to grant announced	Effective date: 20160301
2016-04-13	INTG	Intention to grant announced	Effective date: 20160314
2016-07-15	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2016-07-22	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2016-08-24	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2016-08-24	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2016-08-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 602004049838 Country of ref document: DE Owner name: QINGDAO PRIMEDICINE PHARMACEUTICAL CO., LTD., , CN Free format text: FORMER OWNER: THE UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, BRITISH COLUMBIA, CA
2016-08-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2016-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 823136 Country of ref document: AT Kind code of ref document: T Effective date: 20160915
2016-09-21	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2016-10-06	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602004049838 Country of ref document: DE
2016-12-28	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20160824
2017-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 823136 Country of ref document: AT Kind code of ref document: T Effective date: 20160824
2017-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824
2017-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161226 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161125 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824
2017-03-10	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2605015 Country of ref document: ES Kind code of ref document: T3 Effective date: 20170310
2017-04-13	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 602004049838 Country of ref document: DE Owner name: QINGDAO PRIMEDICINE PHARMACEUTICAL CO., LTD., , CN Free format text: FORMER OWNER: THE UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, BRITISH COLUMBIA, CA Ref country code: DE Ref legal event code: R082 Ref document number: 602004049838 Country of ref document: DE Representative=s name: GRUND INTELLECTUAL PROPERTY GROUP PATENTANWALT, DE
2017-04-24	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13
2017-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824
2017-05-26	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602004049838 Country of ref document: DE
2017-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161124 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824
2017-05-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2017-06-14	REG	Reference to a national code	Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20170518 AND 20170524
2017-06-21	RAP2	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: QINGDAO PRIMEDICINE PHARMACEUTICAL CO., LTD
2017-06-30	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2017-06-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2017-07-26	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2017-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031
2017-08-02	26N	No opposition filed	Effective date: 20170526
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161008 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824
2017-10-23	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14
2017-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161008
2017-12-22	REG	Reference to a national code	Ref country code: FR Ref legal event code: TP Owner name: QINGDAO PRIMEDICINE PHARMACEUTICALS CO LTD, CN Effective date: 20171120
2018-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20041008
2018-06-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824
2018-10-23	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15
2022-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20220914 Year of fee payment: 19
2022-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20220819 Year of fee payment: 19
2023-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20221031 Year of fee payment: 19 Ref country code: ES Payment date: 20221118 Year of fee payment: 19 Ref country code: DE Payment date: 20221020 Year of fee payment: 19
2024-05-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602004049838 Country of ref document: DE
2024-06-26	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20231008
2024-07-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231008
2024-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231008 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231031 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240501
2024-11-27	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20241127
2024-12-03	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231008
2024-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231008
2025-01-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231009
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231009